Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018–2020
Ashley Tippett(Emory University), Erica Anderson(University of Alabama at Birmingham), Sonal Uppal(Pfizer (United States)), Meg Taylor(Emory University), Theda Gibson(Emory University), Olivia Reese(Emory University), W Li(Emory University), Warren V. Kalina(Pfizer (United States)), Christina A. Rostad(Emory University), Luis Jódar(Pfizer (United States)), Luis W Salazar(Emory University), David L. Swerdlow(Pfizer (United States)), Kathleen Stephens(Emory University), Gabby Ess(Emory University), Chris Choi(Emory University), Shadwal Gupta(Emory University), H.-M. Hsiao(Emory University), Robin Hubler(Pfizer (United States)), Elizabeth Grace Taylor(Emory University), Caihua Liang(Pfizer (United States)), Sara S Kim(Emory University), Samadhan Jadhao(Emory University), Larry J Anderson(Emory University), Khalel De Castro(Emory University), Bradford D Gessner(Pfizer (United States)), Elizabeth Begier(Pfizer (United States)), Qing Liu(Pfizer (United States)), Kristin Nelson(Emory University), Nadine Rouphael(Emory University), Pragati Prasad(Centers for Disease Control and Prevention)
Cited by 0
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009
|New England Journal of Medicine|2009|1.7k